Kenneth Mcgrath Acquires 22,021 Shares of OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth Mcgrath acquired 22,021 shares of OraSure Technologies stock in a transaction on Friday, March 13th. The shares were bought at an average price of $3.00 per share, with a total value of $66,063.00. Following the purchase, the chief financial officer directly owned 557,262 shares in the company, valued at approximately $1,671,786. The trade was a 4.11% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

OraSure Technologies Stock Down 4.8%

Shares of OSUR stock opened at $2.98 on Wednesday. OraSure Technologies, Inc. has a 52-week low of $2.08 and a 52-week high of $4.22. The stock has a market cap of $206.00 million, a PE ratio of -3.20 and a beta of 0.88. The business has a 50-day simple moving average of $2.84 and a 200-day simple moving average of $2.79.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The company had revenue of $26.76 million for the quarter, compared to analyst estimates of $26.44 million. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%. Sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.08 earnings per share for the current fiscal year.

Key OraSure Technologies News

Here are the key news stories impacting OraSure Technologies this week:

• Positive Sentiment: Insiders (CEO Carrie Eglinton and CFO Kenneth McGrath) purchased stock on March 13, increasing their holdings — a signal of management confidence that can support the share price. CEO Form 4 CFO Form 4
• Neutral Sentiment: OraSure issued a public rebuttal to Altai Capital, emphasizing operational progress, upcoming regulatory/commercial milestones and ongoing engagement — the company says it has rejected settlement offers and will not cede to a rushed sale process; this is a standard defensive response that reduces uncertainty but doesn’t resolve the activist’s demands. Company Statement
• Negative Sentiment: Activist Altai Capital (≈5% owner) delivered a detailed letter pressing OraSure to explore a sale and seeking board seats, saying the company could fetch materially higher value — this raises near-term takeover speculation, governance fight risk and potential for a forced sale process, which is increasing selling pressure and volatility. Reuters: Altai Presses OraSure BusinessWire: Altai Letter

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $3.00.

Hedge Funds Weigh In On OraSure Technologies

A number of large investors have recently bought and sold shares of the business. Invesco Ltd. raised its holdings in OraSure Technologies by 11.1% in the 4th quarter. Invesco Ltd. now owns 161,182 shares of the medical instruments supplier’s stock worth $390,000 after purchasing an additional 16,041 shares during the period. XTX Topco Ltd grew its holdings in OraSure Technologies by 57.8% in the fourth quarter. XTX Topco Ltd now owns 121,144 shares of the medical instruments supplier’s stock valued at $293,000 after purchasing an additional 44,379 shares during the period. Quadrature Capital Ltd purchased a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $28,000. Numerai GP LLC purchased a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $100,000. Finally, Odyssean LLC acquired a new position in shares of OraSure Technologies during the 4th quarter worth approximately $162,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.